Titan Pharma in General Agreement With FDA on Pathway for Probuphine – the Pharma Letter
Titan Pharma in general agreement with FDA on pathway for Probuphine – The Pharma Letter
The Pharma Letter |
Titan Pharma in general agreement with FDA on pathway for Probuphine
The Pharma Letter The proposed clinical study will be a randomized, double-blind and double-dummy design that will provide information for a non-inferiority comparison of a six-month treatment with a dose of four Probuphine implants to treatment with 8mg or less of an … |
Methadone Maintenance – Google News
Related Methadone Maintenance Information…